Surrozen (SRZN) Assets Average (2020 - 2026)
Surrozen (SRZN) posted quarterly Assets Average of $109.7 million for Q1 2026, up 34.38% year-over-year from $81.6 million in Q1 2025, and up 13.83% quarter-over-quarter from $96.4 million in Q4 2025.
Surrozen (SRZN) Assets Average (2020 - 2026) Analysis & Trends
Surrozen's Assets Average history runs 7 years deep, the most recent figure standing at $109.7 million for Q1 2026.
- In Q1 2026, Assets Average rose 34.38% year-over-year to $109.7 million; the TTM figure through Mar 2026 stood at $109.7 million (up 34.38% YoY), while the FY2025 annual figure was $73.6 million, up 55.68% from the prior year.
- Assets Average for Q1 2026 stood at $109.7 million, up from $96.4 million in the prior quarter.
- The five-year high for Assets Average was $127.4 million in Q1 2022, with the low at $40.9 million in Q2 2024.
- The 5-year median for Assets Average is $81.8 million (2023), against an average of $79.9 million.
- The sharpest annual moves came in 2024 and 2025: Assets Average sank 49.4% in 2024, then surged 165.97% in 2025.
- Surrozen's Assets Average stood at $90.4 million in 2022, then slumped by 44.68% to $50.0 million in 2023, then dropped by 3.59% to $48.2 million in 2024, then jumped by 99.84% to $96.4 million in 2025, then advanced by 13.83% to $109.7 million in 2026.
- Business Quant data shows SRZN's Assets Average at $109.7 million in Q1 2026, $96.4 million in Q4 2025, and $98.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 118.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 118.16 Mn |
| Mar 31, 2026 | 109.72 Mn |
| Dec 31, 2025 | 96.39 Mn |
| Sep 30, 2025 | 98.37 Mn |
| Jun 30, 2025 | 108.76 Mn |
| Mar 31, 2025 | 81.65 Mn |
| Dec 31, 2024 | 48.23 Mn |
| Sep 30, 2024 | 46.53 Mn |
| Jun 30, 2024 | 40.89 Mn |
| Mar 31, 2024 | 41.40 Mn |
| Dec 31, 2023 | 50.03 Mn |
| Sep 30, 2023 | 58.99 Mn |
| Jun 30, 2023 | 69.10 Mn |
| Mar 31, 2023 | 81.82 Mn |
| Dec 31, 2022 | 90.43 Mn |
| Sep 30, 2022 | 97.78 Mn |
| Jun 30, 2022 | 110.89 Mn |
| Mar 31, 2022 | 127.41 Mn |
| Dec 31, 2021 | 143.91 Mn |
| Sep 30, 2021 | 121.79 Mn |